Benjamin G Vincent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3239239/publications.pdf

Version: 2024-02-01

59 papers 8,456 citations

32 h-index 57 g-index

66 all docs 66
docs citations

66 times ranked 14120 citing authors

#	Article	IF	CITATIONS
1	The Immune Landscape of Cancer. Immunity, 2018, 48, 812-830.e14.	6.6	3,706
2	Integrated Molecular Characterization of Testicular Germ Cell Tumors. Cell Reports, 2018, 23, 3392-3406.	2.9	324
3	B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell, 2019, 179, 1191-1206.e21.	13.5	291
4	Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell, 2018, 173, 305-320.e10.	13.5	272
5	Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute, 2016, 108, djw144.	3.0	271
6	Current Landscape of Immunotherapy in Breast Cancer. JAMA Oncology, 2019, 5, 1205.	3.4	260
7	Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight, 2017, 2, .	2.3	257
8	Prognostic B-cell Signatures Using mRNA-Seq in Patients with Subtype-Specific Breast and Ovarian Cancer. Clinical Cancer Research, 2014, 20, 3818-3829.	3.2	230
9	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. Journal of Clinical Investigation, 2018, 128, 4804-4820.	3.9	210
10	Alternative tumour-specific antigens. Nature Reviews Cancer, 2019, 19, 465-478.	12.8	206
11	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight, 2016, 1, e85902.	2.3	179
12	Systematic Analysis of Splice-Site-Creating Mutations in Cancer. Cell Reports, 2018, 23, 270-281.e3.	2.9	177
13	A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases. Clinical Cancer Research, 2017, 23, 250-262.	3.2	159
14	A Dual Immunotherapy Nanoparticle Improves T ell Activation and Cancer Immunotherapy. Advanced Materials, 2018, 30, e1706098.	11.1	130
15	Endogenous retrovirus expression is associated with response to immune checkpoint pathway in clear cell renal cell carcinoma. JCI Insight, 2018, 3, .	2.3	128
16	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. Journal of Experimental Medicine, 2021, 218, .	4.2	84
17	Type 2 innate lymphoid cells treat and prevent acute gastrointestinal graft-versus-host disease. Journal of Clinical Investigation, 2017, 127, 1813-1825.	3.9	84
18	B Cell Function in the Tumor Microenvironment. Annual Review of Immunology, 2022, 40, 169-193.	9.5	84

#	Article	IF	CITATIONS
19	Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. Cancer Research, 2018, 78, 3954-3968.	0.4	82
20	Prognostic value of B cells in cutaneous melanoma. Genome Medicine, 2019, 11, 36.	3.6	81
21	Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS ONE, 2018, 13, e0193832.	1.1	74
22	B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer. Cancer Immunology Research, 2020, 8, 292-308.	1.6	62
23	Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. Bioinformatics, 2016, 32, 3729-3734.	1.8	59
24	Toxin-Coupled MHC Class I Tetramers Can Specifically Ablate Autoreactive CD8+ T Cells and Delay Diabetes in Nonobese Diabetic Mice. Journal of Immunology, 2010, 184, 4196-4204.	0.4	55
25	CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. JCI Insight, 2020, 5, .	2.3	52
26	Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Cancer Immunology Research, 2019, 7, 1591-1604.	1.6	48
27	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. Journal of Clinical Investigation, $2021,131,.$	3.9	43
28	Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. Journal of Clinical Investigation, 2022, 132, .	3.9	43
29	HLAProfiler utilizes k-mer profiles to improve HLA calling accuracy for rare and common alleles in RNA-seq data. Genome Medicine, 2017, 9, 86.	3.6	41
30	Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Blood Cancer Discovery, 2021, 2, 616-629.	2.6	41
31	An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD. Blood, 2017, 130, 2131-2145.	0.6	37
32	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunology Research, 2022, 10, 372-383.	1.6	36
33	Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication. Clinical Cancer Research, 2020, 26, 4260-4267.	3.2	35
34	Pathogenic Bhlhe40+ GM-CSF+ CD4+ T cells promote indirect alloantigen presentation in the GI tract during GVHD. Blood, 2020, 135, 568-581.	0.6	35
35	Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clinical Cancer Research, 2020, 26, 4670-4681.	3.2	31
36	Landscape and selection of vaccine epitopes in SARS-CoV-2. Genome Medicine, 2021, 13, 101.	3.6	30

#	Article	IF	CITATIONS
37	Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Advances, 2018, 2, 2052-2062.	2.5	24
38	Restricted myeloperoxidase epitopes drive the adaptive immune response in MPO-ANCA vasculitis. Journal of Autoimmunity, 2020, 106, 102306.	3.0	21
39	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. Journal of Cancer, 2019, 10, 3344-3351.	1.2	19
40	Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients. International Journal of Molecular Sciences, 2020, 21, 858.	1.8	16
41	Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia. Transplantation and Cellular Therapy, 2021, 27, 1021.e1-1021.e5.	0.6	15
42	NeoSplice: a bioinformatics method for prediction of splice variant neoantigens. Bioinformatics Advances, 2022, 2 , .	0.9	13
43	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight, 2020, 5, .	2.3	11
44	Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. , 2022, 10 , e003427.		11
45	Deletion of naÃ-ve T cells recognizing the minor histocompatibility antigen HY with toxin-coupled peptide-MHC class I tetramers inhibits cognate CTL responses and alters immunodominance. Transplant Immunology, 2013, 29, 138-145.	0.6	10
46	Improved T-cell Receptor Diversity Estimates Associate with Survival and Response to Anti–PD-1 Therapy. Cancer Immunology Research, 2021, 9, 103-112.	1.6	10
47	Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth. Translational Oncology, 2020, 13, 100856.	1.7	9
48	Bronchoalveolar Tregs are associated with duration of mechanical ventilation in acute respiratory distress syndrome. Journal of Translational Medicine, 2020, 18, 427.	1.8	9
49	iWAS – A novel approach to analyzing Next Generation Sequence data for immunology. Cellular Immunology, 2016, 299, 6-13.	1.4	8
50	Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge. JCO Precision Oncology, 2021, 5, 51-54.	1.5	7
51	Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab. Clinical Cancer Research, 2022, 28, 1690-1700.	3.2	7
52	The Use of Peptide-Major-Histocompatibility-Complex Multimers in Type 1 Diabetes Mellitus. Journal of Diabetes Science and Technology, 2012, 6, 515-524.	1.3	6
53	Combination Immunotherapy: A Dual Immunotherapy Nanoparticle Improves Tâ€Cell Activation and Cancer Immunotherapy (Adv. Mater. 25/2018). Advanced Materials, 2018, 30, 1870182.	11.1	4
54	Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. Cancer Gene Therapy, 2022, 29, 683-696.	2.2	4

#	Article	IF	CITATIONS
55	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 591-599.	0.6	4
56	Heparinâ€induced thrombocytopenia associated with collection of hematopoietic progenitor cells by apheresis. Journal of Clinical Apheresis, 2020, 35, 59-61.	0.7	3
57	One Is Better than Two: TCR Pairing and GVHD. Science Translational Medicine, 2013, 5, 188fs21.	5.8	2
58	Delivery strategies for cancer vaccines and immunoadjuvants. , 2022, , 359-408.		1
59	Challenges and Gaps in Clinical Trial Genomic Data Management. JCO Clinical Cancer Informatics, 2022, 6, e2100193.	1.0	0